Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

65 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Treatment Patterns and Outcomes in Follicular Lymphoma with POD24: An Analysis from The LEO Consortium.
Day JR, Larson MC, Durani U, Koff JL, Wang Y, Habermann TM, Lossos IS, Nastoupil LJ, Strouse CS, Chihara D, Martin P, Leonard JP, Cohen JB, Kahl BS, Ruan J, Burack R, Friedberg JW, Cerhan JR, Flowers CR, Link BL, Maurer MJ, Casulo C. Day JR, et al. Among authors: burack r. Blood Adv. 2024 Nov 27:bloodadvances.2024014053. doi: 10.1182/bloodadvances.2024014053. Online ahead of print. Blood Adv. 2024. PMID: 39602301
Efficacy of lenalidomide in high-risk diffuse large B-cell lymphoma.
Rodgers TD, Baran A, Reagan PM, Casulo C, Zent C, Evans A, Burack R, Williams AM, Friedberg JW, Barr PM. Rodgers TD, et al. Among authors: burack r. Br J Haematol. 2020 Feb;188(4):e33-e36. doi: 10.1111/bjh.16302. Epub 2019 Dec 17. Br J Haematol. 2020. PMID: 31845324 Free article. No abstract available.
Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas.
Friedberg JW, Mahadevan D, Cebula E, Persky D, Lossos I, Agarwal AB, Jung J, Burack R, Zhou X, Leonard EJ, Fingert H, Danaee H, Bernstein SH. Friedberg JW, et al. Among authors: burack r. J Clin Oncol. 2014 Jan 1;32(1):44-50. doi: 10.1200/JCO.2012.46.8793. Epub 2013 Sep 16. J Clin Oncol. 2014. PMID: 24043741 Free PMC article. Clinical Trial.
Inhibition of COP9-signalosome (CSN) deneddylating activity and tumor growth of diffuse large B-cell lymphomas by doxycycline.
Pulvino M, Chen L, Oleksyn D, Li J, Compitello G, Rossi R, Spence S, Balakrishnan V, Jordan C, Poligone B, Casulo C, Burack R, Shapiro JL, Bernstein S, Friedberg JW, Deshaies RJ, Land H, Zhao J. Pulvino M, et al. Among authors: burack r. Oncotarget. 2015 Jun 20;6(17):14796-813. doi: 10.18632/oncotarget.4193. Oncotarget. 2015. PMID: 26142707 Free PMC article.
Insertion of atypical glycans into the tumor antigen-binding site identifies DLBCLs with distinct origin and behavior.
Chiodin G, Allen JD, Bryant DJ, Rock P, Martino EA, Valle-Argos B, Duriez PJ, Watanabe Y, Henderson I, Blachly JS, McCann KJ, Strefford JC, Packham G, Geijtenbeek TBH, Figdor CG, Wright GW, Staudt LM, Burack R, Bowden TA, Crispin M, Stevenson FK, Forconi F. Chiodin G, et al. Among authors: burack r. Blood. 2021 Oct 28;138(17):1570-1582. doi: 10.1182/blood.2021012052. Blood. 2021. PMID: 34424958 Free PMC article.
Ipilimumab-Induced Neutropenia in Melanoma.
Ban-Hoefen M, Burack R, Sievert L, Sahasrabudhe D. Ban-Hoefen M, et al. Among authors: burack r. J Investig Med High Impact Case Rep. 2016 Aug 9;4(3):2324709616661835. doi: 10.1177/2324709616661835. eCollection 2016 Jul-Sep. J Investig Med High Impact Case Rep. 2016. PMID: 27570779 Free PMC article.
65 results